Pell Bio-Med Technology (6949) Stock Overview
A biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen receptor T cell (CAR-T), and other related services and products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
6949 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Pell Bio-Med Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$648.00 |
| 52 Week High | NT$620.00 |
| 52 Week Low | NT$90.90 |
| Beta | 0 |
| 1 Month Change | 103.13% |
| 3 Month Change | 75.14% |
| 1 Year Change | 563.93% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 529.13% |
Recent News & Updates
Shareholder Returns
| 6949 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 10.8% | 3.6% | -1.6% |
| 1Y | 563.9% | 14.7% | 38.1% |
Return vs Industry: 6949 exceeded the TW Biotechs industry which returned 14.7% over the past year.
Return vs Market: 6949 exceeded the TW Market which returned 38.1% over the past year.
Price Volatility
| 6949 volatility | |
|---|---|
| 6949 Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in TW Market | 8.9% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6949's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6949's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Steve Lin | www.pellbmt.com |
Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen receptor T cell (CAR-T), and other related services and products. It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors. The company is also involved in the phase 1/2 multicenter study to evaluate the safety and efficacy of CD19-targeted chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell lymphoma; a follow-up study of lentiviral-based gene-edited immune cell therapy.
Pell Bio-Med Technology Co., Ltd. Fundamentals Summary
| 6949 fundamental statistics | |
|---|---|
| Market cap | NT$40.04b |
| Earnings (TTM) | -NT$373.72m |
| Revenue (TTM) | NT$29.99m |
Is 6949 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6949 income statement (TTM) | |
|---|---|
| Revenue | NT$29.99m |
| Cost of Revenue | NT$39.33m |
| Gross Profit | -NT$9.33m |
| Other Expenses | NT$364.38m |
| Earnings | -NT$373.72m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.79 |
| Gross Margin | -31.12% |
| Net Profit Margin | -1,246.01% |
| Debt/Equity Ratio | 8.1% |
How did 6949 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/05 08:14 |
| End of Day Share Price | 2026/02/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pell Bio-Med Technology Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.